A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China

The CARDIAC trial is a prospective, parallel, open-label cluster randomized trial that aims to determine the effectiveness of a coronary computed tomography angiography (CTA)-guided intensive intervention strategy, as compared with standard care, on reducing the incidence of major adverse events (MACE) at 18 months among high-risk cardiovascular populations in rural China. An extended observational follow-up at 36 months will be conducted to further evaluate the effect on long-term clinical outcomes.

NCT Number	NCT07416344
Lead Sponsor	Harbin Medical University Collaborators: Daqing Oil Field Hospital, Heilongjiang Provicial Hospital, The First Hospital Of Qiqihar, Mudanjiang Cardiovascular Hospital, China, Hongqi Hospital Affiliated to Mudanjiang Medical University, The Third Affiliated Hospital of Qiqihar Medical University, The Baoquanling Hospital of Beidahuang Group, Daqing Longnan Hospital, The First Hospital of Suihua City, Jiamusi Central Hospital, Beidahuang Industry Group General Hospital, The First Affiliated Hospital of Jiamusi University, China, Shuangyashan Shuangkuang Hospital, Beijing Peking University WBL Biotech Co., Ltd., Hegang People Hospital
Conditions	Coronary Artery Disease
Enrollment	14,980 participants
Start Date	2026-04-27
Primary Completion	2028-10 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-15